Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration

This article was published in the following Dove Press journal:
Clinical Interventions in Aging
26 May 2017
Number of times this article has been viewed

Stamatina A Kabanarou¹
Tina Xirou¹
George Mangouritsas¹
Christina Garnavou-Xirou²
Eirini Boutouri¹
Ilias Gkizis¹
Irina Chatziralli³

¹Retina Department, Korgialeneio Benakeio, Hellenic Red Cross Hospital, Athens, Greece; ²Retina Department, King’s College Hospital, London, UK; ³2nd Department of Ophthalmology, University of Athens, Athens, Greece

Purpose: Macular hole (MH) is part of a group of age-related degenerative diseases characterized by pathology of vitreomacular interface. Similarly, neovascular age-related macular degeneration (nAMD) affects older patients and is a leading cause of irreversible visual loss. The purpose of this case series is to describe the development of full-thickness MH in patients with nAMD, following antivascular endothelial growth factor (anti-VEGF) treatment.

Methods: Participants in this case series were four patients with nAMD, who received anti-VEGF injections with variable therapeutic response to treatment. Patients were examined at baseline (when AMD was diagnosed) and monthly thereafter. The examination included visual acuity measurement, slit-lamp biomicroscopy, and optical coherence tomography.

Results: All patients were found to develop full-thickness MH within 1–4 months after the last anti-VEGF injection, even in the absence of pre-existing vitreomacular interface abnormalities in some cases. The median number of injections before the MH formation was 3.

Conclusion: MH formation may represent an adverse effect of anti-VEGF treatment in patients with nAMD and could be also coexisting pathology with nAMD in older individuals.

Keywords: macular hole, age-related macular degeneration, anti-VEGF

Introduction

Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in elderly population in the developed world and its prevalence increases with age, ranging from 0.2% (for people aged 55–64 years) to 13% (for those older than 85 years).¹⁻³ Neovascular AMD (nAMD) can lead to visual impairment due to the development of choroidal neovascularization (CNV), and its prevalence is estimated to be 0.17%–5.8%.¹⁻³ Vascular endothelial growth factor (VEGF) is the main angiogenic factor involved in the pathogenesis of nAMD.⁴ Therefore, over the last two decades, intravitreal anti-VEGF agents are considered the standard of care in nAMD, aiming to block CNV activity and consequently prevent vision loss and improve vision in some cases.³ Specifically, the two FDA-approved anti-VEGF agents for nAMD are ranibizumab (Lucentis®; Novartis, Basel, Switzerland), a recombinant antigen-binding fragment that neutralizes all isoforms of VEGF-A,⁶ and aflibercept (Eylea; Bayer Healthcare, Berlin, Germany), which is a recombinant fusion protein consisting of human VEGF receptor extracellular domains from receptors 1 and 2 (VEGFR1 and VEGFR2) fused to the Fc domain of the human IgG backbone and also binded to all isomers of the VEGF-A family, VEGF-B, and placental growth factor.⁷
A small number of ocular adverse events (<1%) have been reported after administration of anti-VEGF injections across large clinical trials, including endophthalmitis, rhegmatogenous retinal detachment, retinal tear, retinal pigment epithelium tear, traumatic cataract, vitreous hemorrhage, and uveitis.58 In addition, full-thickness macular hole (FTMH) formation following anti-VEGF treatment for nAMD has sparsely been reported in the literature, mainly as isolated case reports and mostly in the presence of vitreomacular traction disease.9–15 In light of the above, the purpose of this case series is to describe the development of FTMH in patients with nAMD, following anti-VEGF injections with variable therapeutic responses to treatment, even in the absence of pre-existing vitreomacular interface abnormalities.

Methods
Participants in this retrospective case series were four patients with nAMD, who developed FTMH after intravitreal anti-VEGF injections. Written informed consent was obtained by all participants for participation in this study and publication of the associated images. This study was in accordance with the Tenets of Helsinki Declaration and was approved by the Institutional Review Board of Korgialeneio Benakeio, Hellenic Red Cross Hospital, Athens, Greece. Exclusion criteria were any of the following: CMV of any cause except nAMD, previous FTMH, vitreomacular traction, uveitis, diabetic retinopathy, glaucoma, or retinal vein occlusion.

At baseline, all patients underwent best-corrected visual acuity (BCVA) measurement by means of Snellen charts, ophthalmic examination including slit-lamp biomicroscopy, and using optical coherence tomography (OCT). Time domain (Stratus 3000; Zeiss, Germany) or spectral domain OCT (Heidelberg Spectralis; Heidelberg Engineering, Heidelberg, Germany) were used. Fluorescein angiography (FA) was performed to confirm diagnosis and to exclude other causes of CNV.

All patients received at least one intravitreal injection of either 0.5 mg ranibizumab or 2.0 mg aflibercept. All the injections were performed under standard sterile conditions. Topical antibiotics were administered to all patients four times a day for 1 day before and for 5 days after the injection. Patients were examined monthly thereafter. At each visit, complete eye examination was performed, including BCVA measurement, fundoscopy, and OCT. FA was performed only at the examiner’s discretion and not at every postinjection evaluation.

Results
The patients’ characteristics are shown in Table 1. Of the four patients, two were males and two were females. The mean age of patients was 63.5±4.5 years. All patients presented active CNV with subretinal fluid and pigment epithelium detachment (PED). One patient had posterior vitreous detachment (PVD), and in three patients no PVD was present. Two patients had epiretinal membrane (ERM). At baseline, the mean BCVA was 0.4±0.16 decimal (about 6/12 Snellen). Three patients received ranibizumab and one aflibercept intravitreal injections. All patients developed FTMH about 1–4 months after the last intravitreal injection. Median number of intravitreal injection before developing FTMH was 3. The mean BCVA at the time of FTMH presence was counting fingers in all patients. Figures 1 and 2 showed two indicative cases of our study and their progression over time. No other ocular side effects were found, such as endophthalmitis, inflammation, infection, increased intraocular pressure, retinal tear, or detachment.

Discussion
According to a recent classification of the vitreoretinal interface disorders, FTMH is an anatomic defect in the fovea featuring interruption of all neural retinal layers from the internal limiting membrane to the retinal pigment epithelium.16 Gass17 hypothesized that idiopathic FTMH formation occurred due to focal tangential traction on the fovea, following contraction of the prefoveal vitreous cortex. In addition, Gaudric et al18 demonstrated with OCT that vitreous traction on the fovea may be oblique, whereas Tanner et al19 suggested that initiation of MH formation may be attributed to an anteroposterior vitreofoveal traction

Table 1 Demographic and clinical characteristics of our study sample

<table>
<thead>
<tr>
<th>Case</th>
<th>Age</th>
<th>Gender</th>
<th>Eye</th>
<th>SRF</th>
<th>PED</th>
<th>PVD</th>
<th>ERM</th>
<th>Injection</th>
<th>No of injections</th>
<th>BCVA before</th>
<th>BCVA after</th>
<th>Time after last injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>66</td>
<td>Male</td>
<td>Right</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Ranibizumab</td>
<td>2</td>
<td>0.2</td>
<td>CF</td>
<td>2 months</td>
</tr>
<tr>
<td>2</td>
<td>64</td>
<td>Female</td>
<td>Left</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Ranibizumab</td>
<td>3</td>
<td>0.4</td>
<td>CF</td>
<td>4 months</td>
</tr>
<tr>
<td>3</td>
<td>67</td>
<td>Male</td>
<td>Right</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Aflibercept</td>
<td>3</td>
<td>0.4</td>
<td>CF</td>
<td>1 month</td>
</tr>
<tr>
<td>4</td>
<td>57</td>
<td>Female</td>
<td>Right</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Ranibizumab</td>
<td>3</td>
<td>0.6</td>
<td>CF</td>
<td>1 month</td>
</tr>
</tbody>
</table>

Abbreviations: BCVA, best corrected visual acuity; CF, counting fingers; ERM, epiretinal membrane; PED, pigment epithelium detachment; PVD, posterior vitreous detachment; SRF, subretinal fluid.
documented by OCT imaging. Therefore, both tangential and oblique/anterior–posterior vitreous traction have been implicated in the development of idiopathic FTMH.

The role of abnormal vitreomacular interface in AMD has previously been reported and vitreomacular adhesion, as well as vitreomacular traction has been implicated as potential risk factors for the development of exudative AMD.\(^{20,21}\)

On the contrary, PVD seemed to have a prophylactic effect on AMD formation.\(^{22}\) Furthermore, since currently anti-VEGF agents are the treatment of choice for nAMD, it has been reported that vitreo-retinal traction, if present, could antagonize the effect of anti-VEGF treatment and cause pharmacological resistance in patients with nAMD.\(^{23}\) However, anti-VEGF intravitreal injections can induce PVD in patients with nAMD. Specifically, it has been reported that 24% of patients receiving intravitreal injections for exudative maculopathies, such as nAMD, develop PVD over a mean 11.1-week follow-up period and PVD incidence correlates with increasing age.\(^{24}\)

FTMH formation following intravitreal anti-VEGF treatment for nAMD has been previously reported in the

**Figure 1** 66-year-old male patient with age-related macular degeneration, who developed full thickness macular hole after ranibizumab injections.  
**Notes:** (A) Color fundus photo in a 66-year-old male patient, demonstrating a pigment epithelium detachment at the fovea surrounded by drusen and few retinal haemorrhages in his right eye; (B) early-phase and (C) late-phase fluorescein angiography of the same patient, showing an active choroidal neovascularization; (D) optical coherence tomography, showing subretinal fluid, pigment epithelium detachment, and retinal pigment epithelium changes, as well as disruption in ellipsoid zone; (E) optical coherence tomography two months after the last ranibizumab injection, showing full-thickness macular hole; (G) optical coherence tomography 4 months later, showing the development of disciform scar underneath the macular hole, extending beyond the hole’s edges.

**Figure 2** 57-year-old female patient who developed full thickness macular hole after ranibizumab injections for age-related macular degeneration.  
**Notes:** (A) Optical coherence tomography of a 57-year-old female patient, showing intraretinal fluid overlying a pigment epithelium detachment; (B) optical coherence tomography 1 month after three intravitreal ranibizumab injections, showing full-thickness macular hole with the pigment epithelium detachment remaining at the base of the hole; (C) optical coherence tomography 5 months later, showing stability.
Taking into account the prevalence of wet AMD as previously reported and the large number of patients treated with anti-VEGF injections, more attention should be paid on the possible changes of vitreomacular interface and PVD following anti-VEGF injections. If such a relationship exists, there is a potential risk for MH formation following anti-VEGF treatment. If this risk does exist, it does not outweigh the well-established benefits of anti-VEGF therapy for nAMD. On the other hand, both FTMH and nAMD are age-related conditions with similar prevalence, which increases with age. Therefore, they may represent only coexisting pathologies in the older population and not an adverse effect to anti-VEGF treatment that eventually interact with each other.

**Conclusion**

Taking into account the prevalence of wet AMD as previously reported and the large number of patients treated with

**References**


